FutureCeuticals, an R&D and manufacturing company of fruit, vegetable and grain-based products for the functional food and dietary supplement markets, has opened Applied BioClinical (ABC), a new bioclinical research facility in Irvine, Calif.

Using advanced clinical research tools and equipment, ABC is able to measure the acute and single-dose effect of products on a wide-range of biologically relevant targets, including a host of biomarkers associated with inflammation, aging, cardiovascular conditions and metabolic conditions and serum diagnostics, among others. The ABC testing paradigm allows for the time-efficient, affordable and publishable discoveries of new functions and mechanisms of action for tested products.

"The establishment of Applied BioClinical and our state-of-the-art facilities and clinical discovery research capabilities again demonstrates ongoing investment in and commitment to delivering unique, potent, market-leading ethical products and services," said Dr. Zbigniew Pietrzkowski, chief science officer, and former vice president of R&D at FutureCeuticals. 

While Pietrzkowski and his team will continue to serve as the bioclinical R&D arm of FutureCeuticals, ABC provides a vehicle to make its bioclinical research expertise available to a wider audience within the scientific and business community and offer new opportunities for partnerships focused on co-discovery and product co-development.